The downgrade from Outperform to Sector Perform by RBC Capital indicates a less optimistic outlook for Sangamo Therapeutics. The significant reduction in price target from $6 to $2 also suggests that the analyst believes the stock is overvalued at current levels. This could lead to a negative sentiment among investors, potentially causing a decrease in the stock price in the short term.